Hongene Bio
Established in 1998, Hongene Biotech has been specialized in the production of nucleic acid raw materials for more than 25 years, covering nucleosides and modified nucleosides, nucleotides, phosphonamidites, GalNAc delivery molecules and enzymes. The annual capacity of phosphonamidites is 58 tons and nucleoside triphosphates is 54,000 liters (equivalent of 1.05 billion doses of mRNA vaccines). To date, Hongene has over 1,600 employees globally with over 400 R&D staff. Hongene brand is highly recognized by major pharmaceutical companies and biotech companies developing mRNA and oligonucleotide drugs. Hongene’s products have entered almost all nucleic acid drug pipelines worldwide. During the Covid19 pandemic, Hongene was the largest supplier of raw materials used in billions of mRNA COVID-19 vaccines. Currently, the company has established end-to-end mRNA CDMO capability, provide one stop shopping from raw materials to final product, supporting clients from preclinical research to commercialization.
